| Literature DB >> 29888072 |
Olivier B Poirion1,2, Kumardeep Chaudhary1,2, Lana X Garmire1,3.
Abstract
We propose an unsupervised multi-omics integration pipeline, using deep-learning autoencoder algorithm, to predict the survival subtypes in bladder cancer (BC). We used TCGA dataset comprising mRNA, miRNA and methylation to infer two survival subtypes. We then constructed a supervised classification model to predict the survival subgroups of any new individual sample. Our training data gave two subgroups with significant survival differences (p-value=8e-4), where high-risk survival subgroup was enriched with KRT6/14 overexpression and PI3K-Akt pathways. We tested the robustness of model by randomly splitting the main dataset into multiple training and test folds, which gave overall significant p-values. Then, we successfully inferred the subtypes for a subset of samples kept as test dataset (p-value=0.03). We further applied our pipeline to predict the survival subgroups from another validation dataset with miRNA data (p-value=0.02). Conclusively, present pipeline is an effective approach to infer the survival subtype of a new sample, exemplified by BC.Entities:
Year: 2018 PMID: 29888072 PMCID: PMC5961799
Source DB: PubMed Journal: AMIA Jt Summits Transl Sci Proc
Figure 1Unsupervised inference of the survival subtypes.
Figure 2Supervised classification pipeline to infer the survival subtype, using the predicted labels, for a new sample
Log-rank p-value of Cox-PH models for the training, test and validation datasets. The Cox-PH models were constructed using either the cluster label or the probability to belong the cluster with the lowest survival as single variable.
| Dataset | p-value label | p-value label probability |
|---|---|---|
| Training folds (20 iteration) | 8e-4 (geo. mean) | 7e-4 (geo. mean) |
| Test folds (20 iteration) | 0.04 (geo. mean) | 0.03 (geo. mean) |
| Final training dataset | 0.002 | 0.001 |
| Final test dataset | 0.03 | 0.02 |
| Validation dataset | 0.02 | 0.02 |
Figure 3Survival profiles of the two survival subtypes for the (A) TCGA full cohort and (B) the validation cohort.
Figure 4Molecular signatures of the two survival subtypes. (A) mRNA differential expression (B) miRNA differential expression and (C) Volcano plot of differential methylated genes.
Pathway enrichment analysis for the two subtypes.
| Pathway upregulated in SI | Adjusted lvalue |
|---|---|
| Cytokine-cytokine receptor interaction | 1.97E-13 |
| Staphylococcus aureus infection | 3.91E-07 |
| PI3K-Akt signaling pathway | 3.16E-06 |
| Amoebiasis | 3.77E-06 |
| Complement and coagulation cascades | 3.77E-06 |
| ECM-receptor interaction | 5.13E-06 |
| Hematopoietic cell lineage | 6.61E-05 |
| Focal adhesion | 1.94E-04 |
| Tuberculosis | 2.47E-04 |
| Chemokine signaling pathway | 4.32E-04 |
| Rheumatoid arthritis | 3.03E-04 |
| Jak-STAT signaling pathway | 1.Q8E-03 |
| Cell adhesion molecules (CAMs) | 9.81E-04 |
| Pertussis | 7.78E-04 |
| Osteoclast differentiation | 3.84E-03 |
| Neuroactive ligand-receptor interaction | 4.43E-03 |
| Transcriptional misregulation in cancer | 4.43E-03 |
| Protein digestion and absorption | 3.77E-03 |
| Hypertrophic cardiomyopathy (HCM) | 5.41E-03 |
| Phagosome | 5.41E-03 |
| Leishmaniasis | 7.02E-03 |
| D i lated ca idiom yopat hy | 9.32E-03 |
| Malaria | 7.08E-03 |
| Toll-like receptor signaling pathway | 2.98E-02 |
| Systemic lupus erythematosus | 2.70E-02 |
| Calcium signaling pathway | 4.48E-02 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 2.53E-02 |
| Inflammatory bowel disease (IBD) | 3.56E-02 |
| Prion diseases | 2.35E-02 |
| Graft-versus-host disease | 4.25 E-02 |
| Nicotinate and nicotinamide metabolism | 4.25E-02 |
| Metabolism of xenobiotics by cytochrome P450 | 2.37E-09 |
| Chemical carcinogenesis | 1.15E-09 |
| Retinol metabolism | 7.61E-09 |
| Drug metabolism - cytochrome P450 | 1.12E-08 |
| Steroid hormone biosynthesis | 4.81E-07 |
| PPAR signaling pathway | 2.97E-04 |
| Arachidonic acid metabolism | 1.40E-03 |
| Bile secretion | 2.62E-03 |
| Starch and sucrose metabolism | 5.26E-03 |
| Ascorbateand aldarate metabolism | 3.45 E-03 |
| Metabolic pathways | 1.74E-02 |
| Linoleic acid metabolism | 4.12E-03 |
| Pentose and glucuronate inteiconversions | 8.01E-03 |
| Porphyrin and chlorophyll metabolism | 1.33E-02 |
| Drug metabolism - other enzymes | 1.74E-02 |